

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~striketrough~~
and additions by underlining)

In the Claims

1. (Original) A method of combating cancer in a patient in need of such combating, wherein the cancer is caused by the deregulation of expression of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.

2. (Currently amended) A method of combating cancer in a patient according to claim 1, wherein said ~~the proliferation of cancer cells in a patient in need of such combating, wherein the proliferation is caused by the~~ deregulation of expression results in the proliferation of cancer cells in ~~of proteins having a role in regulating tumor cells, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to~~ said patient and wherein said administering combats the proliferation of said cancer cells.

3. (Currently amended) A method of combating cancer ~~the proliferation of cancer cells in a patient~~ according to claim 2, ~~in need of such combating, wherein said~~ the proliferation of cancer cells is caused by the over-expression of proteins having a role in regulating tumor cells ~~which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~ and wherein said administering combats the proliferation of said cancer cells.

4. (Currently amended) A method of combating cancer in a patient according to claim 2, wherein said ~~the~~ proliferation of cancer cells has ~~having~~ an aggressive phenotype in said ~~a~~ patient [[,]] wherein said aggressive phenotype is the result of ~~in need of such combating, wherein the proliferation is caused by the over-expression of peripheral-type~~

12. (Original) A method according to claim 7, wherein said cancer cells are human colonic carcinoma cells.

13. (Original) A method according to claim 7, wherein said cancer cells are human colonic adenocarcinoma cells.

14. (Original) A method according to claim 7, wherein said cancer cells are human ovarian carcinoma cells.

15. (Original) A method according to claim 7, wherein said cancer cells are human hepatocellular carcinoma cells.

16. (Currently amended) A method according to claim 7,
wherein the ~~of~~-decreasing of the expression of peripheral-
type benzodiazepine receptor is the result of decreasing the
expression of peripheral-type benzodiazepine receptor mRNA
in cancer cells[[]] in a patient in need of such
decreasing, which comprises administering an effective
amount of Ginkgo biloba extracts or isolated Ginkgolide B to
said patient.

17. (Currently amended) A method of combating cancer in a
patient according to claim 1, wherein said deregulation of
increasing the expression results in increasing the
expression of [[a]] c-Myc protooncogene[[]] in a patient in
need of such increasing, which comprises administering an
effective amount of Ginkgo biloba extracts or isolated
Ginkgolide B to said patient.

18. (Currently amended) A method of combating cancer in a
patient according to claim 1, wherein said deregulation of
decreasing the expression results in decreasing the
expression of cell cycle regulators prothymosin- α , CDK2,
p55CDC, myeloblastin and p120 proliferating-cell nuclear
antigen[[]] in a patient in need of such decreasing, which
comprises administering an effective amount of Ginkgo biloba
extracts or isolated Ginkgolide B to said patient.

19. (Currently amended) A method of combating cancer in a
patient according to claim 1, wherein said deregulation of
decreasing the expression results in decreasing the
expression of intracellular signal transduction modulators
NET1 and ERK2[[]], in a patient in need of such decreasing,

benzodiazepine receptor protein and wherein said administering combats the proliferation of said cancer cells. ~~, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

5. (Currently amended) A method of combating ~~the proliferation of cancer~~ in a patient according to claim 2, ~~cells, wherein said where the proliferation of cells is~~ caused by the over-expression of oncogenes, and wherein the administering results in ~~[[by]]~~ decreasing the expression of said oncogenes and combats the proliferation of said cancer cells. ~~in a patient in need of such combating, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

6. (Original) A method according to claim 5, wherein said oncogenes are one or more of APC, PE-1, RhoA and c-Jun.

7. (Currently amended) A method of combating ~~decreasing the expression of peripheral type benzodiazepine receptor in~~ cancer cells ~~in a patient~~ according to claim 1, wherein said deregulation of the expression of proteins results in need of such decreasing, wherein said cancer cells express expressing an abnormal level of peripheral-type benzodiazepine receptor relative to normal cancer cells, wherein said administering results in decreasing the expression of peripheral-type benzodiazepine receptor in cancer cells. ~~which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

8. (Original) A method according to claim 7, wherein said cancer cells are human breast cancer cells.

9. (Original) A method according to claim 7, wherein said cancer cells are glioblastomas.

10. (Original) A method according to claim 7, wherein said cancer cells are human brain tumor cells.

11. (Original) A method according to claim 7, wherein said cancer cells are human astrocytoma cells.

~~which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

20. (Currently amended) A method of combating cancer in a patient according to claim 1, wherein said deregulation of decreasing the expression results in decreasing the expression of apoptosis-related products Adenosine A2A

Receptor, Flt3 ligand, Grb2, Clusterin, RXR- β , Glutathione S-transferase P, N-Myc, TRADD, SGP-2 and NIP-1[[.]], ~~in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

21. (Currently amended) A method of combating cancer in a patient according to claim 1, wherein said deregulation of decreasing the expression results in decreasing the expression of transcription factors Id-2, ATF-4, ETR101 and ETR-103[[.]] ~~in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

22. (Currently amended) A method of combating cancer in a patient according to claim 1, wherein said deregulation of decreasing the expression results in decreasing the expression of growth factors macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein and inhibin α [[.]], ~~in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

23. (Currently amended) A method of combating cancer in a patient according to claim 1, wherein said deregulation of decreasing the expression results in decreasing the expression of cell adhesion molecules CD19 B-lymphocyte antigen, L1CAM, β -catenin, integrin subunits $\alpha 3$, $\alpha 4$, $\alpha 6$, $\beta 5$, and αM [[.]], ~~in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

24. (Currently amended) A method of combating cancer in a patient according to claim 1, wherein said deregulation of decreasing the expression results in decreasing the expression of genes APC, PE-1, RhoA, c-Jun, prothymosin- α , CDK2, p55CDC, myeloblastin, p120 proliferating-cell nuclear antigen, NET1, ERK2, Adenosine A2A Receptor, Flt3 ligand, Grb2, Clusterin, RXR- β , Glutathione S-transferase P, N-Myc, TRADD, SGP-2, NIP-1, Id-2, ATF-4, ETR-101, ETR-103, macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein, inhibin α , CD19 B-lymphocyte antigen, L1CAM, β -catenin, and integrin subunits α 3, α 4, α 6, β 5, and α M[[.]], ~~in a patient in need of such decreasing, which comprises administering an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B to said patient.~~

25. (Currently amended) A pharmaceutical composition useful for combating cancer in a patient according to claim 1, comprising an effective amount of Ginkgo biloba extracts or isolated Ginkgolide B for combating cancer and a pharmaceutically acceptable carrier or diluent.